Pillutla, R
(PubMed) (PubMed) Miller JW, Rucker RB
Reidy Physician Assistant, Certified (PA-C) Laura C
Immunogenicity of BYDUREON in Pediatric Patients In a 52-week BYDUREON trial (24-week controlled and 28-week extended treatment period) for the improvement of glycemic control in pediatric patients with type 2 diabetes mellitus (Trial 9) [see Clinical Studies (14.6)], 37/58 (64%) of BYDUREON-treated patients had high titer anti-exenatide antibodies (high titer was defined as 625) at any time during the study
Of those assigned the active, 10 were White, 6 were Black, 2 were Asian, and 3 were of Latin descent
In contrast, curcumin has demonstrated coordinated inhibition of DNMTs (DNMT1, DNMT3A, DNMT3B), suppression of histone deacetylases (HDAC1, HDAC3), and modulation of non-coding RNAs and m 6 A RNA methylation within the same cellular context